{
  "retracted": false,
  "timestamp": 1566259200000,
  "updates": [
    {
      "timestamp": 1566290486249,
      "identifier": {
        "doi": "10.1007/s12094-019-02198-5"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s12094-019-02166-z"
  },
  "journal": "Clinical and Translational Oncology",
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy"
}
